← Back to Search

Hormone Therapy

Videos for Type 1 Diabetes

N/A
Waitlist Available
Led By Claudia Gagnon, Dr
Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Parent or primary caregiver of a child or adolescent (<18 years old) diagnosed with type 1 diabetes OR Any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, animators, teacher candidates, etc.)
Legal age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through the simulation completion, 3 months after listening to the videos
Awards & highlights

Study Summary

This trial is comparing the performance of administering intranasal versus injectable glucagon after a short video training among parents/primary caregivers and school workers.

Eligible Conditions
  • Type 1 Diabetes
  • Low Blood Sugar

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the interview completion, 3 months after listening to the videos
This trial's timeline: 3 weeks for screening, Varies for treatment, and through the interview completion, 3 months after listening to the videos for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Success rate of glucagon administration
Time to complete preparation and administration of the glucagon
Secondary outcome measures
Barriers related to the use of intranasal and injectable glucagon in both groups
Emotional impact (fears, perceptions, stress, etc.) related to the use of intranasal and injectable glucagon in both groups
Preferences in relation to the teaching method of administering the two forms of glucagon
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: "School workers" groupExperimental Treatment3 Interventions
Any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, facilitators, teacher candidates, etc.). This individual must not meet the criteria for the "parent" group.
Group II: "Parents" groupExperimental Treatment3 Interventions
Parent or primary caregiver of a child or adolescent (<18 years old) diagnosed with type 1 diabetes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Simulation
2021
N/A
~580
Interview
2017
N/A
~1510
Videos
2021
Completed Phase 2
~960

Find a Location

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
166 Previous Clinical Trials
106,934 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,333 Previous Clinical Trials
25,747,298 Total Patients Enrolled
Juvenile Diabetes Research FoundationOTHER
231 Previous Clinical Trials
111,677 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many test subjects are receiving treatment during the course of this trial?

"Correct. Evidence hosted on clinicaltrials.gov indicates that this medical experiment, which was initially published on March 19th 2021, is currently admitting participants. Approximately 60 patients need to be recruited from 1 research centre."

Answered by AI

Are new participants being accepted for this clinical experiment?

"Information posted on clinicaltrials.gov reveals that this particular medical experiment is actively searching for patients to enroll in the program, with its first appearance being on March 19th 2021 and a recent update taking place on May 26th 2022."

Answered by AI
~15 spots leftby Mar 2025